| Code | CSB-RA006044MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to cabiralizumab, targeting the colony-stimulating factor 1 receptor (CSF1R). CSF1R is a cell surface tyrosine kinase receptor that plays a crucial role in the survival, proliferation, and differentiation of macrophages and monocytes. Upon binding its ligands CSF1 and IL-34, CSF1R activates signaling pathways that regulate the tumor microenvironment by controlling tumor-associated macrophages (TAMs). Elevated CSF1R expression and increased TAM infiltration are associated with poor prognosis in various solid tumors, including pancreatic cancer, glioblastoma, and diffuse-type tenosynovial giant cell tumor.
Cabiralizumab is a humanized IgG4 monoclonal antibody that blocks CSF1R signaling by preventing ligand binding, thereby depleting immunosuppressive TAMs within the tumor microenvironment. This biosimilar antibody serves as a valuable research tool for investigating CSF1R-mediated immune regulation, studying macrophage biology in cancer models, and exploring combination immunotherapy strategies. It enables researchers to examine the therapeutic potential of CSF1R inhibition across various disease contexts.
There are currently no reviews for this product.